[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $CLLS--CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud

ATLANTA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cellectis

[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, to

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder righ

Law Offices of Howard G. Smith announces an investigation on behalf of Cellectis S.A. (“Cellectisâ

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Cellect

Analysts downgraded NU, BAK, CLLS and CBZ; price targets for NU, BAK and CLLS were cut sharply.

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with severa

Barclays analyst Lukas Shumway downgrades Cellectis (NASDAQ:CLLS) from Overweight to Underweight

Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market ses

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mix

Wells Fargo analyst Yanan Zhu maintains Cellectis (NASDAQ:CLLS) with a Equal-Weight and lowers th

Baird analyst Jack Allen maintains Cellectis (NASDAQ:CLLS) with a Outperform and lowers the pric

Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other s

Cellectis S.A. (NASDAQ: CLLS - Get Free Report)'s stock price crossed below its 50-day moving averag

Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday'

Cellectis S.A. (CLLS) Discusses Strategic Transformation and In Vivo Gene Editing Pipeline Update Tr

U.S. stocks fell Monday as tech slid; Nvidia may invest $10B in Anthropic’s IPO. Oil rose 3%, while

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 200 points on Mon

U.S. stocks fell Monday, led by a 2% tech decline. Nvidia may invest $10B in Anthropic; oil jumped 4

Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipe

Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday&

U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 500 points on

U.S. stock futures fell, with Nasdaq 100 futures down 500 points. Corning dropped 8% after a $2B off

Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premark

Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NAS

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NAS

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.19) per share which beat the analyst consen

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDA

EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pi

Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ:CLLS) with a Overweight ra

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pi

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.16) per share which beat the analyst consen

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pi

Citizens analyst Silvan Turkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and m

Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to d

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

Clear Street analyst Bill Maughan initiates coverage on Cellectis (NASDAQ:CLLS) with a Buy rating